Healthy Volunteers [clinicaltrials_resource:dbb6df173fe31a3aee2083ed96dfbd0e]
Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses [clinicaltrials:NCT00001257]The Body's Affect on Vitamin C [clinicaltrials:NCT00001309]Tissue Biopsy and Imaging Studies in HIV-Infected Patients [clinicaltrials:NCT00001471]Blood Component Collection From Patients With Rheumatic Disease and Healthy Volunteers [clinicaltrials:NCT00031174]Urinary Vitamin C Loss in Diabetic Subjects [clinicaltrials:NCT00071526]Dose-Response of Gonadal Steroids and Bone Turnover in Men [clinicaltrials:NCT00114114]Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers [clinicaltrials:NCT00152724]Metabolic Capacity of Israeli Populations [clinicaltrials:NCT00162383]Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over [clinicaltrials:NCT00170768]Regulation of the Release of Inflammatory Mediators From Blood Leukocytes [clinicaltrials:NCT00180765]Parameters Associated With the Emergence of Resistance to Ciprofloxacin in Human Commensal Flora [clinicaltrials:NCT00190151]Cardiac Water and Fluoromethane Cardiac PET [clinicaltrials:NCT00205127]Effects of DHEA and Exercise in the Elderly [clinicaltrials:NCT00205686]The Effects of Increased Central Serotonergic Activity on Information Processing [clinicaltrials:NCT00206934]The Effect of Imipramine on Early Information Processing [clinicaltrials:NCT00206999]Glutamine and Intestinal Protein Metabolism [clinicaltrials:NCT00213551]Effect of Yohimbine on Colon Transit [clinicaltrials:NCT00217048]Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers [clinicaltrials:NCT00223483]Prediction of Drug Interactions With CYP2C9 Substrates [clinicaltrials:NCT00226538]Vaporization as a Smokeless Cannabis Delivery System [clinicaltrials:NCT00241592]A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects [clinicaltrials:NCT00251030]Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine [clinicaltrials:NCT00256347]The Diameter of the Middle Cerebral Artery Measured With Magnetic Resonance Angiography [clinicaltrials:NCT00256802]Glyceryl-Trinitrate-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2 [clinicaltrials:NCT00257985]Safety Study Comparing a Vaccine Transcutaneous Administration to the Intramuscular Route [clinicaltrials:NCT00261001]PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY [clinicaltrials:NCT00263523]Reference Values for Plasma Catechols [clinicaltrials:NCT00267904]Local Anesthetic Properties of Neosaxitoxin [clinicaltrials:NCT00273065]Transcranial Electrical Stimulation (TCES) / Cerebral Blood Flow (CBF) / Xenon Under Computerized Tomography (Xe/CT) [clinicaltrials:NCT00273663]Use of MRI for Assessing Stomach Relaxation in Response to a Meal [clinicaltrials:NCT00275743]The Effect of Contrast Media on Erythrocytes in Healthy Volunteers [clinicaltrials:NCT00285506]Study of Celecoxib Bioavailability in Healthy Subjects [clinicaltrials:NCT00296127]A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults [clinicaltrials:NCT00301639]A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults [clinicaltrials:NCT00302354]An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects [clinicaltrials:NCT00302367]A Study to Evaluate the Effect of a Medicine on Gastric Functions in Healthy Volunteers. [clinicaltrials:NCT00308399]Thorough QT Study of Nelfinavir [clinicaltrials:NCT00312182]Thyroid and Fat Tissue Metabolism [clinicaltrials:NCT00312715]Long-Term Improvement in Motor Learning by Transcranial Direct Current Stimulation [clinicaltrials:NCT00314769]Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers [clinicaltrials:NCT00332956]
condition [clinicaltrials_vocabulary:condition]
eligibility for clinicaltrials:NCT01217918 [clinicaltrials_resource:14b19841cbf7f26b31fa3122a7ac559c]eligibility for clinicaltrials:NCT00838422 [clinicaltrials_resource:2feaa149dd2343b3c853dad539c75fd7]eligibility for clinicaltrials:NCT00966862 [clinicaltrials_resource:3b76587ae55bb00aae0777cb831da78b]eligibility for clinicaltrials:NCT02443727 [clinicaltrials_resource:3c9c04796fbd8d04e897933b1654288e]eligibility for clinicaltrials:NCT02337777 [clinicaltrials_resource:3d4f4199b909685a708b735d04f2bf94]eligibility for clinicaltrials:NCT00556920 [clinicaltrials_resource:4669bc4ca6bde816b3ff12d70ebf9953]eligibility for clinicaltrials:NCT00489957 [clinicaltrials_resource:4efbe72da817f7b7eea9adcb3bc64168]eligibility for clinicaltrials:NCT02325804 [clinicaltrials_resource:567a03814b22e7fc205ed485804d42fc]eligibility for clinicaltrials:NCT00913250 [clinicaltrials_resource:66bc287b2ea4b09408430f5a9e3ffb8f]eligibility for clinicaltrials:NCT01393652 [clinicaltrials_resource:67dfce69998862aaf1a54ce0483f290a]eligibility for clinicaltrials:NCT00994461 [clinicaltrials_resource:7cbb9c07eeeb09118d142158c5ff0216]eligibility for clinicaltrials:NCT01992380 [clinicaltrials_resource:8effc52a44cf8f47643269d3f08c9d73]eligibility for clinicaltrials:NCT00651105 [clinicaltrials_resource:93c0bdfd994f1333e6eb77df2970feee]eligibility for clinicaltrials:NCT02385331 [clinicaltrials_resource:9638cc0582e51bafc3668c898199af66]eligibility for clinicaltrials:NCT00688012 [clinicaltrials_resource:9ce868926b52b88108ef0a01778f4a4c]eligibility for clinicaltrials:NCT00673023 [clinicaltrials_resource:a154fcc49be5388cd2a2342b11a411e1]eligibility for clinicaltrials:NCT00353990 [clinicaltrials_resource:b4c72e9be45c8254a401d55a0756fac3]eligibility for clinicaltrials:NCT00966784 [clinicaltrials_resource:c7c97cf23eaa4e0391602f508acee46a]eligibility for clinicaltrials:NCT01452906 [clinicaltrials_resource:cf232ce80594d735ddcbfd6651f0d50f]eligibility for clinicaltrials:NCT01164904 [clinicaltrials_resource:f3ee4d5105eb3bac9b92e27f3c30b337]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT01217918 [clinicaltrials_resource:14b19841cbf7f26b31fa3122a7ac559c]eligibility for clinicaltrials:NCT00838422 [clinicaltrials_resource:2feaa149dd2343b3c853dad539c75fd7]eligibility for clinicaltrials:NCT00966862 [clinicaltrials_resource:3b76587ae55bb00aae0777cb831da78b]eligibility for clinicaltrials:NCT02443727 [clinicaltrials_resource:3c9c04796fbd8d04e897933b1654288e]eligibility for clinicaltrials:NCT02337777 [clinicaltrials_resource:3d4f4199b909685a708b735d04f2bf94]eligibility for clinicaltrials:NCT00556920 [clinicaltrials_resource:4669bc4ca6bde816b3ff12d70ebf9953]eligibility for clinicaltrials:NCT00489957 [clinicaltrials_resource:4efbe72da817f7b7eea9adcb3bc64168]eligibility for clinicaltrials:NCT02325804 [clinicaltrials_resource:567a03814b22e7fc205ed485804d42fc]eligibility for clinicaltrials:NCT00913250 [clinicaltrials_resource:66bc287b2ea4b09408430f5a9e3ffb8f]eligibility for clinicaltrials:NCT01393652 [clinicaltrials_resource:67dfce69998862aaf1a54ce0483f290a]eligibility for clinicaltrials:NCT01321411 [clinicaltrials_resource:79cccb8ec7a1d862d3fd7c19400edf04]eligibility for clinicaltrials:NCT00994461 [clinicaltrials_resource:7cbb9c07eeeb09118d142158c5ff0216]eligibility for clinicaltrials:NCT01992380 [clinicaltrials_resource:8effc52a44cf8f47643269d3f08c9d73]eligibility for clinicaltrials:NCT00651105 [clinicaltrials_resource:93c0bdfd994f1333e6eb77df2970feee]eligibility for clinicaltrials:NCT02385331 [clinicaltrials_resource:9638cc0582e51bafc3668c898199af66]eligibility for clinicaltrials:NCT00688012 [clinicaltrials_resource:9ce868926b52b88108ef0a01778f4a4c]eligibility for clinicaltrials:NCT00673023 [clinicaltrials_resource:a154fcc49be5388cd2a2342b11a411e1]eligibility for clinicaltrials:NCT00353990 [clinicaltrials_resource:b4c72e9be45c8254a401d55a0756fac3]eligibility for clinicaltrials:NCT00966784 [clinicaltrials_resource:c7c97cf23eaa4e0391602f508acee46a]eligibility for clinicaltrials:NCT01452906 [clinicaltrials_resource:cf232ce80594d735ddcbfd6651f0d50f]eligibility for clinicaltrials:NCT01164904 [clinicaltrials_resource:f3ee4d5105eb3bac9b92e27f3c30b337]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Healthy Volunteers [clinicaltrials_resource:dbb6df173fe31a3aee2083ed96dfbd0e]
Bio2RDF identifier
dbb6df173fe31a3aee2083ed96dfbd0e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:dbb6df173fe31a3aee2083ed96dfbd0e
identifier
clinicaltrials_resource:dbb6df173fe31a3aee2083ed96dfbd0e
title
Healthy Volunteers
@en
label
Healthy Volunteers [clinicaltrials_resource:dbb6df173fe31a3aee2083ed96dfbd0e]
@en